Summary of the invention
It is diagnosed and is swallowed by detection ZACN gene or protein expression difference one of the objects of the present invention is to provide one kind
The method of cancer.
The second object of the present invention is to provide one kind by detection ZACN gene or protein expression difference to predict to swallow
The method of cancer prognosis.
The third object of the present invention, which is to provide, a kind of treats hypopharyngeal cancer by inhibiting ZACN gene or ZACN albumen
Method.
The fourth object of the present invention is to provide a kind of method for screening the drug for the treatment of hypopharyngeal cancer.
The fifth object of the present invention is to provide a kind of for treating the drug of hypopharyngeal cancer.
To achieve the goals above, present invention employs following technical solutions:
The present invention provides the products of detection ZACN gene or ZACN albumen to prepare the purposes in hypopharyngeal cancer diagnostic tool.
The present invention also provides the products of detection ZACN gene or ZACN albumen in preparation prediction hypopharyngeal cancer prognostic tool
Purposes.
Further, the product of the detection ZACN gene or ZACN albumen includes the table for detecting ZACN gene or ZACN albumen
Up to horizontal product.The product includes the nucleic acid that can combine ZACN gene or the substance (example that can combine ZACN albumen
Such as antibody).The nucleic acid is able to detect the expression of ZACN gene;The substance is able to detect the expression water of ZACN albumen
It is flat.
The product of detection ZACN gene of the invention can play its function based on the known method of nucleic acid molecules is used: such as
PCR, such as Southern hybridization, Northern hybridization, dot blot, fluorescence in situ hybridization (FISH), DNA microarray, ASO method, height
Flux microarray dataset etc..It can qualitatively, quantitatively or semi-quantitatively implement analysis using the product.
Include that nucleic acid in the said goods can be obtained by chemical synthesis, or by containing from biomaterial preparation
It is expected that the gene of nucleic acid, then using primer amplification designed for amplification expectation nucleic acid, it is obtained.
Further, the PCR method is known method, for example, ARMS (Amplification Refractory
Abruptly-changing system is not answered in Mutation System, amplification) method, RT-PCR (reverse transcriptase-PCR) method, nesting PCR method etc..Amplification
Nucleic acid can be by using dot blotting hybridization method, Surface Plasmon Resonance (SPR method), PCR-RFLP method, original position RT-PCR
Method, PCR-SSO (sequence specific oligonucleotide) method, PCR-SSP method, AMPFLP (amplifiable fragment length polymorphism) method,
MVR-PCR method and PCR-SSCP (single-strand conformation polymorphism) method detect.
Nucleic acid recited above includes the primer for expanding ZACN gene, and the primer for including in product can be by passing through chemistry
Synthesis to prepare, by using those skilled in the art will know that method be suitably designed with reference to Given information, and passing through
Synthesis is learned to prepare.
In specific embodiments of the present invention, the nucleic acid is amplimer used in QPCR experiment, the primer
Sequence such as SEQ ID NO.1 (positive sequence) and SEQ ID NO.2 (reverse sequence) shown in.
Nucleic acid recited above may also include probe, and the probe can be prepared by chemical synthesis, by using this
The method that field technical staff knows appropriately is designed with reference to Given information, and is prepared by chemical synthesis, or can lead to
The gene for containing desired nucleic acid sequence from biomaterial preparation is crossed, and is expanded using the primer designed for amplification expectation nucleic acid sequence
Increase it to prepare.
The product of detection ZACN albumen of the invention can play its function based on the known method of antibody is used: for example,
It may include ELISA, radioimmunoassay, immunohistochemical method, western blot etc..
The product of detection ZACN albumen of the invention includes the antibody or its segment for specifically binding ZACN albumen.It can make
With the antibody or its segment of any structure and size, immunoglobulin class, origin etc., as long as it combines target protein.This
The antibody or its segment for including in the testing product of invention can be monoclonal or polyclonal.Antibody fragment refers to reservation antibody
Peptide to the active antibody of the combination of antigen a part of (Partial Fragment) or containing antibody a part.Antibody fragment may include F
(ab′)2, Fab ', Fab, scFv (scFv), the Fv (dsFv) of disulphide bonding or its polymer, the area dimerization V it is (dual anti-
Body) or peptide containing CDR.The product of detection ZACN albumen of the invention may include encoding antibody or Encoding Antibody Fragment
The isolated nucleic acid of amino acid sequence, the carrier comprising the nucleic acid, and carry the cell of the carrier.
Antibody can be obtained by the way that well known to a person skilled in the art methods.For example, preparation retains target all or in part
The mammalian cell expression vector of their polynucleotides of the polypeptide or integration coding of protein is as antigen.Exempted from using antigen
After epidemic disease animal, from the immune animal adaptive immune cell of process and myeloma cell is merged to obtain hybridoma.Then from hybridization
Tumor culture collects antibody.It can finally be implemented by using antibody of the ZACN albumen for being used as antigen or part thereof to acquisition
Antigentic specificity purifies to obtain the monoclonal antibody for ZACN albumen.Polyclonal antibody can be prepared as follows: with it is above
Identical antigen-immunized animal collects blood sample from by immune animal, serum is isolated from blood, then using upper
It states antigen and antigentic specificity purifying is implemented to serum.It can be by the antibody that is obtained with enzymatic treatment or by using the antibody of acquisition
Sequence information obtain antibody fragment.
The combination of marker and antibody or its segment can be implemented by method as commonly known in the art.For example, can
With following fluorescent marker protein or peptide: clean protein or peptide with phosphate buffer, addition DMSO, buffer, etc. standards
Standby dyestuff, then mixed solution, then at being placed at room temperature for 10 minutes.In addition, the labelling kit of commercialization can be used in label, it is all
Such as biotin labeling reagent box, such as biotin labeling reagent box-NH2, biotin labeling reagent box-SH
(DojindoLaboratories);Alkali phosphatase enzyme mark kit such as alkali phosphatase enzyme mark kit-NH2, alkaline phosphorus
Sour enzyme labelling kit-SH (Dojindo Laboratories);Peroxidase labelling kit such as peroxidase mark
Remember kit-NH2, peroxidase labelling kit-NH2 (Dojindo Laboratories);Phycobniliprotein labelled reagent
Box such as phycobniliprotein labelling kit-NH2, phycobniliprotein labelling kit-SH, B- phycoerythrin labelling kit-NH2,
B- phycoerythrin labelling kit-SH, R-PE labelling kit-NH2, R-PE labelling kit SH
(DojindoLaboratories);Fluorescent labeling reagent box such as fluorescein labelling kit-NH2, HiLyte Fluor (TM)
555 labelling kit-NH2,647 labelling kit-NH2 of HiLyte Fluor (TM) (Dojindo Laboratories);And
DyLight 547 and DyLight647 (Techno Chemical Corp.), Zenon (TM), Alexa Fluor (TM) antibody
Labelling kit, Qdot (TM) antibody labeling kit (Invitrogen Corporation) and EZ- marker protein mark
Remember kit (Funakoshi Corporation).For correct labeling, suitable instrument can be used to detect by label
Antibody or its segment.
As the sample according to testing product of the invention, the tissue sample for example obtained from biopsy subject can be used
Or fluid.Sample is not particularly limited, as long as it is suitable for measurement of the invention;For example, it may include tissue, blood, blood plasma,
Serum, lymph, urine, serous cavity liquid, spinal fluid, synovia, aqueous humor, tear, saliva or its fraction or treated material
Material.
In specific embodiments of the present invention, tissue of the sample from subject.
In the present invention, " prognosis " refers to mistake of the tumor patient after inhibiting by surgical procedure etc. or alleviating tumour growth
Journey or result.In the present specification, prognosis can be by surgical procedure inhibit or alleviate tumour growth after 1,2,3,4,5,6,
7,8,9,10,15,20 years or more long when life state.Prognosis can be by checking biomarker, that is, ZACN albumen or coding
The gene of ZACN albumen is predicted.Prognosis prediction can be performed such that according to biomarker with or without or increasing or drop
It is low, determine that the prognosis of patient is good or bad, or determine the probability of good prognosis or poor prognosis.
In the present invention, " prognosis bona " refer to inhibit or alleviate for patient by surgical procedure etc. tumour growth it
Afterwards, patient's long-term (such as 3,5,6,7,8,9,10,15,20 years or longer) does not have critical condition.Alternatively, good prognosis can anticipate
Refer to and survives in such long-time, sent out again without transfer, without recurrence or nothing.For example, prognosis bona can mean at least 3 years or outstanding
It is to survive at least 5 years, preferably without transfer or recurrence.The most preferred state of prognosis bona is survival for a long time without disease.Such as
Used herein, " prognosis bona " can also include any such state, wherein it can be found that disease such as shifts, still
It is pernicious low and do not severely impact survival ability.
In the present invention, " prognosis mala " refers to that patient is short after inhibiting or alleviating tumour growth by surgical procedure etc.
Fatal condition occurs in period (such as 1,2,3,4,5 year or shorter).Alternatively, poor prognosis refers in such short-term extremely
It dies, shift, recur or sends out again.For example, poor prognosis can mean Preventive or dead at least 3 years or especially at least 5 years
It dies.
Prediction prognosis is referred to the process of prediction status of patient or as a result, is not meant to be predicted with 100% accuracy
The process or result of status of patient.Prediction prognosis refers to whether a possibility that determining certain processes or result increases, and simultaneously unexpectedly
Taste by determining a possibility that certain processes or result occurs or not compared with certain processes or result.Such as this
For invention, in the present invention in the raised patient of the level of ZACN gene or ZACN albumen, with the patient's phase for not showing this feature
Than more likely observing particular procedure or result.
Further, the product of the detection ZACN gene or ZACN albumen can be detection ZACN gene or ZACN albumen
Reagent is also possible to include kit, chip, test paper of the reagent etc., is also possible to measure using the high pass of the reagent
Sequence platform.
The present invention also provides a kind of tool for diagnosing hypopharyngeal cancer, the tool is able to detect ZACN gene or ZACN albumen
Expression.The tool include can in conjunction with ZACN gene nucleic acid or can in conjunction with ZACN albumen substance (such as
Antibody).The nucleic acid is able to detect the expression of ZACN gene;The substance is able to detect the expression of ZACN albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the diagnosis hypopharyngeal cancer includes but is not limited to chip, kit, test paper or high-flux sequence
Platform;High-flux sequence platform is a kind of tool of special diagnosis hypopharyngeal cancer, with the development of high throughput sequencing technologies, to one
The building of personal gene expression profile will become very easily work.By the gene table for comparing Disease and normal population
Up to spectrum, the exception for being easy to analyze which gene is related to disease.Therefore, the exception of ZACN gene is known in high-flux sequence
The purposes for also belonging to ZACN gene related to hypopharyngeal cancer, equally within protection scope of the present invention.
The present invention also provides a kind of tools for predicting hypopharyngeal cancer prognosis, and the prediction hypopharyngeal cancer prognostic tool includes can
In conjunction with ZACN gene nucleic acid or can in conjunction with ZACN albumen substance (such as antibody).The nucleic acid is able to detect ZACN base
The mRNA level in-site of cause;The substance is able to detect the expression of ZACN albumen.
Further, the property of the nucleic acid and the substance is the same as noted earlier.
Further, the tool of the prediction hypopharyngeal cancer prognosis includes but is not limited to chip, kit, test paper or high throughput
Microarray dataset;High-flux sequence platform is a kind of tool of special diagnosis hypopharyngeal cancer, with the development of high throughput sequencing technologies,
Very easily work will be become to the building of the gene expression profile of a people.By the base for comparing Disease and normal population
Because of express spectra, the exception for being easy to analyze which gene is related to disease.Therefore, ZACN gene is known in high-flux sequence
The abnormal purposes for also belonging to ZACN gene related to hypopharyngeal cancer, equally within protection scope of the present invention.
The number for the amino acid that anti-ZACN antibody used in testing product of the invention, diagnostic tool or its segment are identified
Mesh is not particularly limited, as long as antibody can combine ZACN.When antibody is as therapeutic agent, preferably it can know
Amino acid not as much as possible, as long as it can inhibit ZACN function.The number of antibody or the amino acid of its segment identification is at least
One, more preferably at least three.The immunoglobulin class of antibody is unrestricted, can be IgG, IgM, IgA, IgE, IgD or
IgY。
The present invention also provides a kind of diagnosis hypopharyngeal cancer or the methods for predicting hypopharyngeal cancer prognosis, and the method includes walking as follows
It is rapid:
(1) sample of subject is obtained;
(2) expression of ZACN gene or albumen in Samples subjects is detected;
(3) it associates whether by the expression of the ZACN gene or albumen that measure with the illness of subject.
(4) compared with the control, the expression of ZACN gene or albumen increases, then the subject is diagnosed as hypopharyngeal cancer,
Or the subject is confirmed as prognosis mala.
The present invention also provides a kind for the treatment of methods of hypopharyngeal cancer, and the method includes inhibiting ZACN gene or ZACN egg
It is white.
Further, the method includes inhibiting the expression of ZACN gene, or expression or the inhibition ZACN of inhibition ZACN albumen
The activity of albumen.
The present invention also provides a kind of screening techniques of tumour medicine, can be by adding testing drug to tumour cell
Afterwards or in the expression water to some period measurement ZACN gene or ZACN albumen after tumor model animal application testing drug
It puts down to measure tumour medicine and improve the effect of tumor prognosis.More specifically, when ZACN gene or the expression water of ZACN albumen
It puts down when being reduced after addition or application testing drug or when restoring normal level, the drug may be selected as improvement tumor prognosis
Therapeutic agent.
The present invention also provides a kind of drugs of inhibitor containing ZACN gene or ZACN albumen.
The present invention also provides application of the above-mentioned inhibitor in the drug of preparation treatment hypopharyngeal cancer.
The inhibitor of ZACN gene or ZACN albumen of the invention is unrestricted, as long as can inhibit ZACN or be related to
The expression or activity of the substance of the upstream ZACN or downstream pathway, and for treating the effective drug of tumour.
Further, the inhibitor includes antisense nucleic acid, dsRNA, ribozyme, aptamer, ZACN binding protein segment or antibody
Or its segment.
" antisense nucleic acid " refers to the nucleic acid containing the sequence complementary with the coding mRNA of ZACN.Antisense nucleic acid can by DNA,
RNA or both composition.Antisense nucleic acid does not need complementary with the mRNA100% of target ZACN.Antisense nucleic acid can contain Non-complementary bases,
As long as it being capable of specific hybrid under strict conditions.When antisense nucleic acid is introduced cell, it combines target polynucleotide
And inhibit transcription, RNA processing, translation or stability.In addition to antisense polynucleotides, antisense nucleic acid further includes polynucleotides simulation
Object, it contains by the main chain of modification and 3 ' and 5 ' end parts.Such antisense nucleic acid can be according to ZACN sequence information come just
It generates when design and using well known to a person skilled in the art methods.
" dsRNA " refers to containing duplex-RNA constructs, by RNA interference (RNAi) come the RNA of inhibition of gene expression, including
SiRNA (short interfering rna) and shRNA (short hairpin RNA).DsRNA does not need the homology for having 100% with target-gene sequence,
As long as it can inhibit expression of target gene.In order to stabilize or other purposes, a part of dsRNA can be substituted with DNA.
Preferably, siRNA is the double-stranded RNA of 21-23 base.SiRNA can by well known to a person skilled in the art method come
Preparation, such as by chemical synthesis or as the analog of naturally occurring RNA.ShRNA is with hair clip corner (hairpin
Turn) the Short interfering RNA of structure.ShRNA can be prepared by the way that well known to a person skilled in the art methods, such as be closed by chemistry
Cell and DNA is expressed at or by introducing the DNA for encoding shRNA.
" ribozyme " refers to the RNA with catalytic activity, it can cut, paste, insertion and transfer RNA.The structure of ribozyme can
To include tup, hair clip etc..
" aptamer " refers to the nucleic acid in conjunction with something such as protein.Aptamer can be RNA or DNA.The form of nucleic acid can be with
It is double-strand or single-stranded.The infinite in length system of aptamer, as long as it can specifically bind target molecule, can by such as 10 to
200 nucleotide, preferably 10 to 100 nucleotide, more preferable 15 to 80 nucleotide, even more preferably 15 to 50 nucleosides
Acid composition.Aptamer can be used that well known to a person skilled in the art methods to select.For example, (index can be passed through using SELEX
The phyletic evolution for the ligand that formula enrichment carries out).
" the protein-bonded segment of ZACN " refers in conjunction with ZACN and inhibition ZACN implements the segment of the protein of original function.
Drug of the invention can be used as medicine and be administered alone or apply together with other medicines.It can be with medicine of the invention
The other medicines that object is applied together are unrestricted, as long as it does not damage therapeutic or preventive medicine effect of the invention i.e.
It can, it is preferred that the drug for treating or preventing tumour may include such as alkylating agent, such as ifosfamide, ring phosphinylidyne
Amine, Dacarbazine, Temozolomide, Nimustine, busulfan, procarbazine, melphalan and Ranimustine;Antimetabolite, such as
Enocitabine, capecitabine, Carmofur, Cladribine, gemcitabine, cytarabine, cytarabine octadecyl phosphate
(cytarabine ocfosfate), Tegafur, tegafur-Uracil, Tegafur gimeracil oteracil potassium, deoxidation fluorine urine
Glycosides, hydroxycarbamide, fluorouracil, fludarabine, pemetrexed, Pentostatin, mercaptopurine and methotrexate (MTX);Plant alkaloid, it is all
As Irinotecan, Etoposide, Sobuzoxane, docetaxel, nogitecan, Palmer altruism, vinorelbine, eldisine and
Vincaleukoblastinum;Antitumor antibiotic, such as actinomycin D, Aclarubicin, Amrubicin, idarubicin, epirubicin, Zinostatin
Stimalamer, daunorubicin, Doxorubicin, pirarubicin, bleomycin, Peplomycin, mitomycin C and mitoxantrone;
Drug based on platinum, such as oxaliplatin, carboplatin, cis-platinum and Nedaplatin;Hormonal medicaments, such as Anastrozole, Exemestane,
Estramustine, ethinyloestradiol, chlormadinone, Goserelin, tamoxifen, dexamethasone, Toremifene, Bicalutamide, Flutamide,
Prednisolone, Fosfestrol, mitotane, methyltestosterone, Medroxyprogesterone, Mepitiostane, Leuprorelin and Letrozole;Biological respinse modification
Agent, such as interferon-' alpha ', interferon beta, interferon gamma, interleukin, ubenimex, dry BCG and lentinan;With molecular targeted medicine
Object, such as Imatinib (imatinib), Gefitinib (gefitinib), gemtuzumab, ozogamicin, Tamibarotene, song
Appropriate monoclonal antibody, Tretinoin, bortezomib (bortezomib) and Rituximab etc..
Drug of the invention can be prepared into various dosage forms as needed.Including but not limited to, percutaneous, mucous membrane, nose, buccal,
Tablet, solution, granule, patch, paste, capsule, aerosol or suppository sublingual or orally use.
The administration method of drug of the invention is unrestricted, as long as it can play desired therapeutic effect or preventive effect i.e.
Can, including but not limited to intravenously, in peritonaeum, intraocularly, intra-arterial, intrapulmonary is taken orally, in vesicle, intramuscular, intratracheally, subcutaneously
, local by pleura by skin, sucking, by mucous membrane, skin, stomach is intra-articular, intra-ventricle, rectum, vagina,
In skull, in urethra, in liver, in tumor.In some cases, it can systematically be administered.It is locally to be administered in some cases.
The dosage of drug of the invention is unrestricted, can as long as obtaining desired therapeutic effect or preventive effect
To carry out appropriate determination according to symptom, gender, age etc..Example can be used in the dosage of therapeutic agent or prophylactic agent of the invention
Such as the therapeutic effect of disease or preventive effect are determined as index.
In the context of the present invention, " diagnosis hypopharyngeal cancer " both included judge subject whether suffered from hypopharyngeal cancer or
Including judging that subject whether there is the risk with hypopharyngeal cancer.
" treatment " used herein is covered treatment-related in such as mankind of the mammal with related disease or illness
Disease or morbid state, and include:
(1) prevent disease or morbid state occurs in mammals, especially when the mammal is susceptible in the disease
Diseased state, but when being not yet diagnosed with this morbid state;
(2) inhibit disease or morbid state, that is, prevent its generation;Or
(3) alleviate disease or morbid state, even if disease or morbid state subside.
Term " treatment " is usually directed to treatment mankind or animal (for example, being applied by animal doctor), wherein can reach certain pre-
The therapeutic effect of phase, for example, inhibiting the development (including reduce development speed, stop development) of illness, improving illness and healing
Illness.It further include the treatment as precautionary measures (such as prevention).To not yet development be illness but have development be the illness endanger
The purposes of the patient of danger, is also included in term " treatment ".
The advantages of the present invention:
Of the invention has found a kind of molecular marker for diagnosing hypopharyngeal cancer, can be in hypopharyngeal cancer using the molecular marker
The early stage of generation can be used as judging, provide the survival rate of patient.
In addition, the present invention is capable of providing significant information to determine treatment side for patient by the prognosis of prediction patient
Case strategy.
Of the invention includes that the therapeutic agent of the inhibitor of ZACN gene or albumen can be used as the medicine of new hypopharyngeal cancer
Object.